Sanober Nusrat, MD
Internal Medicine · Oklahoma City, OKNPI 1326560038
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $815 of the $1,137 with a category attached, or 71.7%. It is spread thinly across 12 manufacturers, the largest accounting for just 23.3%. 2025 is the largest year on record at $332, 3.1 times the $106 reported in 2020.
Across 24 payments — averaging $47.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$265
- Incyte Corporation$152
- Johnson & Johnson$125
- Pfizer$112
- AstraZeneca$111
- Amgen$93
- plus $279 from 6 others
What the payments were for
- Food & beverage$81572%
- Education$32228%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 3 | $265 |
| Incyte Corporation | 4 | $152 |
| Johnson & Johnson | 1 | $125 |
| Pfizer | 5 | $112 |
| AstraZeneca | 2 | $111 |
| Amgen | 2 | $93 |
| Octapharma USA, Inc. | 1 | $82 |
| Astellas Pharma US Inc | 1 | $62 |
| CSL Behring | 1 | $50 |
| Sobi, Inc | 2 | $40 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Morphosys, US Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,137 in reported general payments places this provider in the 70th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxyurea | 17 | $316 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Oklahoma City
- Ryan MorganOklahoma City$235K
- Ali JafryOklahoma City$33K
- Samid FarooquiOklahoma City$20K
- Dale BratzlerOklahoma City$17K
- Karen ChopraOklahoma City$16K
- Charlsie RecordOklahoma City$14K
- Jeannette KelleyOklahoma City$14K
- Zain Ul Abideen AsadOklahoma City$14K
- Stuart SchraderOklahoma City$12K
- Patrick GarrisonOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.